These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
28. Isatuximab for the treatment of relapsed/refractory multiple myeloma. Richardson PG; Beksaç M; Špička I; Mikhael J Expert Opin Biol Ther; 2020 Dec; 20(12):1395-1404. PubMed ID: 33111607 [TBL] [Abstract][Full Text] [Related]
29. Balancing the CD38 Expression on Effector and Target Cells in Daratumumab-Mediated NK Cell ADCC against Multiple Myeloma. Lejeune M; Duray E; Peipp M; Clémenceau B; Baron F; Beguin Y; Caers J Cancers (Basel); 2021 Jun; 13(12):. PubMed ID: 34203012 [TBL] [Abstract][Full Text] [Related]
30. Therapeutic Opportunities with Pharmacological Inhibition of CD38 with Isatuximab. Martin TG; Corzo K; Chiron M; Velde HV; Abbadessa G; Campana F; Solanki M; Meng R; Lee H; Wiederschain D; Zhu C; Rak A; Anderson KC Cells; 2019 Nov; 8(12):. PubMed ID: 31779273 [TBL] [Abstract][Full Text] [Related]
31. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. Attal M; Richardson PG; Rajkumar SV; San-Miguel J; Beksac M; Spicka I; Leleu X; Schjesvold F; Moreau P; Dimopoulos MA; Huang JS; Minarik J; Cavo M; Prince HM; Macé S; Corzo KP; Campana F; Le-Guennec S; Dubin F; Anderson KC; Lancet; 2019 Dec; 394(10214):2096-2107. PubMed ID: 31735560 [TBL] [Abstract][Full Text] [Related]
32. Monoclonal Antibody: A New Treatment Strategy against Multiple Myeloma. Cho SF; Lin L; Xing L; Yu T; Wen K; Anderson KC; Tai YT Antibodies (Basel); 2017 Nov; 6(4):. PubMed ID: 31548533 [TBL] [Abstract][Full Text] [Related]
33. Monoclonal Antibodies and Antibody Drug Conjugates in Multiple Myeloma. Radocha J; van de Donk NWCJ; Weisel K Cancers (Basel); 2021 Mar; 13(7):. PubMed ID: 33805481 [TBL] [Abstract][Full Text] [Related]
34. Isatuximab in the Treatment of Multiple Myeloma: A Review and Comparison With Daratumumab. Shen F; Shen W Technol Cancer Res Treat; 2022; 21():15330338221106563. PubMed ID: 35903924 [TBL] [Abstract][Full Text] [Related]
35. Crystal structure of CD38 in complex with daratumumab, a first-in-class anti-CD38 antibody drug for treating multiple myeloma. Lee HT; Kim Y; Park UB; Jeong TJ; Lee SH; Heo YS Biochem Biophys Res Commun; 2021 Jan; 536():26-31. PubMed ID: 33360095 [TBL] [Abstract][Full Text] [Related]
36. Monoclonal Antibodies in the Treatment of Multiple Myeloma. van de Donk NWCJ; Zweegman S Hematol Oncol Clin North Am; 2024 Apr; 38(2):337-360. PubMed ID: 38151402 [TBL] [Abstract][Full Text] [Related]
37. Daratumumab for the treatment of multiple myeloma. Touzeau C; Moreau P Expert Opin Biol Ther; 2017 Jul; 17(7):887-893. PubMed ID: 28434255 [TBL] [Abstract][Full Text] [Related]
38. Isatuximab for the treatment of multiple myeloma. Goldsmith SR; Liu L; Covut F Drugs Today (Barc); 2021 Nov; 57(11):665-675. PubMed ID: 34821880 [TBL] [Abstract][Full Text] [Related]
39. CD38 antibodies in multiple myeloma: back to the future. van de Donk NWCJ; Richardson PG; Malavasi F Blood; 2018 Jan; 131(1):13-29. PubMed ID: 29118010 [TBL] [Abstract][Full Text] [Related]
40. Real-world experience with isatuximab in the treatment of relapsed-refractory multiple myeloma: a case series from the Grand Duchy of Luxembourg. De Wilde S; Plawny L; Berchem G Hematology; 2023 Dec; 28(1):2182098. PubMed ID: 36880781 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]